Important safety information about Xalkori (crizotinib)

26 August 2022 – In consultation with Swissmedic, Pfizer AG informs about the following safety-relevant issues: Visual disturbances are a known risk with crizotinib. Because paediatric patients may not spontaneously report or notice changes in vision, healthcare professionals should inform patients and caregivers about the symptoms of visual disturbances and the risk of vision loss and urge them to contact an ophthalmologist if visual symptoms or vision loss occur. Paediatric patients should be monitored for visual disturbances. Before starting treatment with Xalkori, an ophthalmic assessment should be performed.

For more information, see here.